Correlation between Pre Biopsy Serum Prostate Specific Antigen Level and Gleason Score in Patients Diagnosed with Prostate Adenocarcinoma: A Hospital Based Study

Abstract

Prostate Specific Antigen (PSA) is a non-invasive biomarker in the management of prostate adenocarcinoma. Due to its low specificity, its diagnostic role is controversial in prostate adenocarcinoma. Gleason score is considered as most powerful predictor of prostate carcinoma. PSA in combination with Gleason grading system improves the detection of pathological stage of prostate adenocarcinoma. Objective: To determine the degree of correlation between pre biopsy serum PSA level and Gleason score in patients diagnosed with prostate adenocarcinoma. Methods: Retrospective cross sectional study was conducted in Chemical Pathology and Histopathology department, Sheikh Zayed Hospital, Rahim Yar Khan between July 1, 2021 and September 31, 2022. A total of 51 histopathologically confirmed cases of prostate adenocarcinoma with documented Pre biopsy PSA level and Gleason score were included in the study. Serum PSA level correlation is compared with Gleason score, Gleason Pattern and Gleason Grade. p-value ≤0.05 taken as significant. Results: Mean age for prostate carcinoma patients was 65.71±10.062 years. Mean pre biopsy serum PSA level in study subjects was 40.31±37.52ng/ml. Of the total 51 study subjects, 27 (52.94%) were having Gleason score 7 suggestive of moderately differentiated tumor. Among these, 15(55.6%) were having serum PSA level between 10.01-50.00ng/ml. Statistically significant good correlation of serum PSA with Gleason score, Gleason pattern and Grade was established with p value <0.05. Conclusion: It was concluded that there is good degree of positive correlation between pre biopsy PSA level and Gleason score in patients with Prostate adenocarcinoma